MX2017004637A - Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt. - Google Patents
Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.Info
- Publication number
- MX2017004637A MX2017004637A MX2017004637A MX2017004637A MX2017004637A MX 2017004637 A MX2017004637 A MX 2017004637A MX 2017004637 A MX2017004637 A MX 2017004637A MX 2017004637 A MX2017004637 A MX 2017004637A MX 2017004637 A MX2017004637 A MX 2017004637A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- compounds
- signalling pathway
- wnt signalling
- acetamide derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000019491 signal transduction Effects 0.000 title abstract 3
- MIQSEHQDHNIQNF-UHFFFAOYSA-N N-(2H-pyridin-1-yl)acetamide Chemical class CC(=O)NN1CC=CC=C1 MIQSEHQDHNIQNF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 241001481760 Erethizon dorsatum Species 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 101100408855 Mus musculus Porcn gene Proteins 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La invención está relacionada a compuestos; más específicamente, la invención está relacionada a compuestos útiles como inhibidores de la vía de señalización Wnt; específicamente, los inhibidores de Porcupino (Porcn) son contemplados en la invención; además, la invención contempla procesos para preparar los compuestos y usos de los compuestos; los compuestos de la invención pueden por lo tanto ser utilizados en el tratamiento de condiciones mediadas por la vía de señalización Wnt, por ejemplo, para tratar cáncer, sarcoma, melanoma, cáncer de piel, tumores hematológicos, linfoma, carcinoma, y leucemia; o mejorar la efectividad de un tratamiento anti-cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417829.7A GB201417829D0 (en) | 2014-10-08 | 2014-10-08 | Compounds |
| GBGB1511387.1A GB201511387D0 (en) | 2015-06-29 | 2015-06-29 | Compounds |
| PCT/GB2015/052939 WO2016055786A1 (en) | 2014-10-08 | 2015-10-08 | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004637A true MX2017004637A (es) | 2017-06-30 |
Family
ID=54337304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004637A MX2017004637A (es) | 2014-10-08 | 2015-10-08 | Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt. |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10047079B2 (es) |
| EP (1) | EP3204378B3 (es) |
| JP (2) | JP6722178B2 (es) |
| KR (1) | KR102525131B1 (es) |
| CN (1) | CN107108565B (es) |
| AU (1) | AU2015329784C1 (es) |
| CA (1) | CA2960446C (es) |
| CY (1) | CY1122243T1 (es) |
| DK (1) | DK3204378T6 (es) |
| EA (1) | EA034822B9 (es) |
| ES (1) | ES2754349T7 (es) |
| HR (1) | HRP20191826T4 (es) |
| HU (1) | HUE046914T2 (es) |
| IL (1) | IL251131B (es) |
| LT (1) | LT3204378T (es) |
| MX (1) | MX2017004637A (es) |
| PH (1) | PH12017500611A1 (es) |
| PL (1) | PL3204378T6 (es) |
| PT (1) | PT3204378T (es) |
| SG (1) | SG11201701837UA (es) |
| SI (1) | SI3204378T1 (es) |
| WO (1) | WO2016055786A1 (es) |
| ZA (1) | ZA201701842B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795157B (zh) | 2014-10-08 | 2019-07-23 | 莱德克斯制药公共有限公司 | 作为Wnt信号传送途径的抑制剂的N-吡啶基乙酰胺衍生物 |
| HUE046914T2 (hu) | 2014-10-08 | 2020-04-28 | Redx Pharma Plc | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US10793544B2 (en) | 2016-09-01 | 2020-10-06 | The Board Of Regents Of The University Of Texas System | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| JP2019064975A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| JP7184383B2 (ja) * | 2018-02-01 | 2022-12-06 | ザ・ユニバーシティ・オブ・シドニー | 抗癌性化合物 |
| MA54133B1 (fr) | 2018-03-08 | 2022-01-31 | Incyte Corp | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| JP2023508907A (ja) | 2019-12-20 | 2023-03-06 | テナヤ セラピューティクス， インコーポレイテッド | フルオロアルキル－オキサジアゾールおよびその使用 |
| WO2022094477A1 (en) * | 2020-11-02 | 2022-05-05 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancers having dysregulated wnt signaling pathways |
| GB202100526D0 (en) | 2021-01-15 | 2021-03-03 | Redx Pharma Plc | Pharmaceutical formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
| CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| SE0203654D0 (sv) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| EP1802608A1 (en) | 2004-10-12 | 2007-07-04 | AstraZeneca AB | Quinazoline derivatives for use against cancer |
| WO2008137408A1 (en) * | 2007-04-30 | 2008-11-13 | Genentech, Inc. | Pyrazole inhibitors of wnt signaling |
| JP2011506445A (ja) | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| BR112014020233A2 (pt) * | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
| GB2513403A (en) | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| HUE046914T2 (hu) | 2014-10-08 | 2020-04-28 | Redx Pharma Plc | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai |
| CN106795157B (zh) | 2014-10-08 | 2019-07-23 | 莱德克斯制药公共有限公司 | 作为Wnt信号传送途径的抑制剂的N-吡啶基乙酰胺衍生物 |
-
2015
- 2015-10-08 HU HUE15782041A patent/HUE046914T2/hu unknown
- 2015-10-08 LT LT15782041T patent/LT3204378T/lt unknown
- 2015-10-08 ES ES15782041T patent/ES2754349T7/es active Active
- 2015-10-08 US US15/514,046 patent/US10047079B2/en active Active
- 2015-10-08 DK DK15782041.6T patent/DK3204378T6/da active
- 2015-10-08 PT PT157820416T patent/PT3204378T/pt unknown
- 2015-10-08 KR KR1020177011823A patent/KR102525131B1/ko active IP Right Grant
- 2015-10-08 EP EP15782041.6A patent/EP3204378B3/en active Active
- 2015-10-08 PL PL15782041.6T patent/PL3204378T6/pl unknown
- 2015-10-08 CN CN201580054724.7A patent/CN107108565B/zh active Active
- 2015-10-08 MX MX2017004637A patent/MX2017004637A/es active IP Right Grant
- 2015-10-08 EA EA201790637A patent/EA034822B9/ru unknown
- 2015-10-08 HR HRP20191826TT patent/HRP20191826T4/hr unknown
- 2015-10-08 SG SG11201701837UA patent/SG11201701837UA/en unknown
- 2015-10-08 WO PCT/GB2015/052939 patent/WO2016055786A1/en active Application Filing
- 2015-10-08 CA CA2960446A patent/CA2960446C/en active Active
- 2015-10-08 SI SI201530941T patent/SI3204378T1/sl unknown
- 2015-10-08 JP JP2017518951A patent/JP6722178B2/ja active Active
- 2015-10-08 AU AU2015329784A patent/AU2015329784C1/en active Active
-
2017
- 2017-03-13 IL IL251131A patent/IL251131B/en active IP Right Grant
- 2017-03-15 ZA ZA2017/01842A patent/ZA201701842B/en unknown
- 2017-04-03 PH PH12017500611A patent/PH12017500611A1/en unknown
-
2018
- 2018-07-17 US US16/037,879 patent/US10793560B2/en active Active
-
2019
- 2019-10-10 CY CY20191101069T patent/CY1122243T1/el unknown
-
2020
- 2020-02-17 JP JP2020024726A patent/JP2020090542A/ja not_active Withdrawn
- 2020-09-01 US US17/009,322 patent/US11643408B2/en active Active
-
2023
- 2023-04-03 US US18/130,059 patent/US20230365549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004639A (es) | Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt. | |
| PH12017500611A1 (en) | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway | |
| CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
| MX2019000200A (es) | Agentes antiproliferativos basados en pirimidina. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| TR201909887T4 (tr) | ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri. | |
| IL261015B (en) | History of methylamine as lysyl oxidase inhibitors for cancer treatment | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| MX2015011374A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| PH12016501422A1 (en) | Functionalised benzopyran compounds and use thereof | |
| PH12019500070A1 (en) | Uses of indolinone compounds | |
| SG10201900564WA (en) | Methods for treating cancer | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |